PT1853296E - Utilização de um undecapeptídeo cíclico para a preparação de um medicamento para administração em situações de miocardia isquêmica - Google Patents
Utilização de um undecapeptídeo cíclico para a preparação de um medicamento para administração em situações de miocardia isquêmica Download PDFInfo
- Publication number
- PT1853296E PT1853296E PT06704161T PT06704161T PT1853296E PT 1853296 E PT1853296 E PT 1853296E PT 06704161 T PT06704161 T PT 06704161T PT 06704161 T PT06704161 T PT 06704161T PT 1853296 E PT1853296 E PT 1853296E
- Authority
- PT
- Portugal
- Prior art keywords
- cyclic undecapeptide
- undecapeptide
- formula
- cyclic
- reperfusion
- Prior art date
Links
- 125000004122 cyclic group Chemical group 0.000 title claims description 40
- 239000003814 drug Substances 0.000 title claims description 16
- 230000002107 myocardial effect Effects 0.000 title description 17
- 238000002360 preparation method Methods 0.000 title description 6
- 230000000302 ischemic effect Effects 0.000 title description 5
- 230000010410 reperfusion Effects 0.000 claims description 33
- 230000017531 blood circulation Effects 0.000 claims description 16
- 208000031225 myocardial ischemia Diseases 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 206010040047 Sepsis Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 210000002216 heart Anatomy 0.000 claims description 10
- 230000004064 dysfunction Effects 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 206010040070 Septic Shock Diseases 0.000 claims description 7
- 210000001367 artery Anatomy 0.000 claims description 7
- 230000000747 cardiac effect Effects 0.000 claims description 7
- 230000036303 septic shock Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 5
- 208000001953 Hypotension Diseases 0.000 claims description 4
- 230000036543 hypotension Effects 0.000 claims description 4
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 238000007887 coronary angioplasty Methods 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 230000003257 anti-anginal effect Effects 0.000 claims description 2
- 230000020764 fibrinolysis Effects 0.000 claims description 2
- 210000002064 heart cell Anatomy 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000004081 narcotic agent Substances 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 239000002574 poison Substances 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 230000007574 infarction Effects 0.000 description 15
- 208000028867 ischemia Diseases 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- 208000010125 myocardial infarction Diseases 0.000 description 11
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 229930105110 Cyclosporin A Natural products 0.000 description 8
- 210000004165 myocardium Anatomy 0.000 description 8
- 108010036949 Cyclosporine Proteins 0.000 description 7
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 7
- 229960001265 ciclosporin Drugs 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010058558 Hypoperfusion Diseases 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000003293 cardioprotective effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 2
- LNOBZXNCABUBKK-UHFFFAOYSA-N 2,3,5-triphenyltetrazolium Chemical compound C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 LNOBZXNCABUBKK-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010069140 Myocardial depression Diseases 0.000 description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 2
- 208000033774 Ventricular Remodeling Diseases 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011449 brick Substances 0.000 description 2
- 230000035598 contractile recovery Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- -1 glutathione Chemical compound 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000010016 myocardial function Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000010411 postconditioning Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- AHQFCPOIMVMDEZ-UNISNWAASA-N (e,2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical compound CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241001538513 Caerulea Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000000135 Cardiovascular Syphilis Diseases 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GDFAOVXKHJXLEI-UHFFFAOYSA-N L-N-Boc-N-methylalanine Natural products CNC(C)C(O)=O GDFAOVXKHJXLEI-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000007247 enzymatic mechanism Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 210000003767 ileocecal valve Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000037050 permeability transition Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05000357 | 2005-01-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1853296E true PT1853296E (pt) | 2012-09-26 |
Family
ID=34933239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT06704161T PT1853296E (pt) | 2005-01-10 | 2006-01-10 | Utilização de um undecapeptídeo cíclico para a preparação de um medicamento para administração em situações de miocardia isquêmica |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8889629B2 (enExample) |
| EP (1) | EP1853296B1 (enExample) |
| JP (1) | JP2008526816A (enExample) |
| DK (1) | DK1853296T5 (enExample) |
| ES (1) | ES2387682T3 (enExample) |
| PL (1) | PL1853296T3 (enExample) |
| PT (1) | PT1853296E (enExample) |
| SI (1) | SI1853296T1 (enExample) |
| WO (1) | WO2006072639A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2023948A1 (en) * | 2006-05-04 | 2009-02-18 | Michel Ovize | Use of cyclosporin a or melle4-cyclosporin for the treatment of acute myocardial infarction |
| WO2009098533A1 (en) * | 2008-02-08 | 2009-08-13 | Debiopharm Sa | Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy |
| WO2011141891A1 (en) | 2010-05-12 | 2011-11-17 | Debio Recherche Pharmaceutique S.A. | Use of cycloundecadepsipeptide compounds |
| GB201217560D0 (en) | 2012-10-02 | 2012-11-14 | Mitopharm Ltd | Novel cyclic depsipeptide compounds and their uses |
| EP2967567B1 (en) * | 2013-03-15 | 2022-08-24 | Boston Scientific Scimed, Inc. | System for controlling a tissue-stapling operation with pressurized fluid |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999019471A1 (en) * | 1997-10-16 | 1999-04-22 | Board Of Regents, The University Of Texas System | Models and treatments for cardiac hypertrophy in relation with nf-at3 function |
| KR20030078886A (ko) * | 1998-02-27 | 2003-10-08 | 화이자 프로덕츠 인크. | 허혈 치료용 ｎ-[(치환된 5원 트리아자 이불포화고리)카르보닐] 구아니딘 유도체 |
| AU759480B2 (en) * | 1998-07-01 | 2003-04-17 | Debiopharm S.A. | Novel cyclosporin with improved activity profile |
| AU2125300A (en) * | 1999-02-05 | 2000-08-25 | Debiopharm S.A. | Cyclosporin derivatives and method for the production of said derivatives |
-
2006
- 2006-01-10 PL PL06704161T patent/PL1853296T3/pl unknown
- 2006-01-10 JP JP2007549909A patent/JP2008526816A/ja active Pending
- 2006-01-10 US US11/794,245 patent/US8889629B2/en not_active Expired - Fee Related
- 2006-01-10 WO PCT/EP2006/050140 patent/WO2006072639A1/fr not_active Ceased
- 2006-01-10 ES ES06704161T patent/ES2387682T3/es active Active
- 2006-01-10 EP EP06704161A patent/EP1853296B1/fr active Active
- 2006-01-10 PT PT06704161T patent/PT1853296E/pt unknown
- 2006-01-10 SI SI200631402T patent/SI1853296T1/sl unknown
- 2006-01-10 DK DK06704161.6T patent/DK1853296T5/da active
Also Published As
| Publication number | Publication date |
|---|---|
| SI1853296T1 (sl) | 2012-10-30 |
| DK1853296T3 (da) | 2012-09-03 |
| ES2387682T3 (es) | 2012-09-28 |
| US8889629B2 (en) | 2014-11-18 |
| EP1853296A1 (fr) | 2007-11-14 |
| EP1853296B1 (fr) | 2012-06-20 |
| JP2008526816A (ja) | 2008-07-24 |
| US20090023640A1 (en) | 2009-01-22 |
| PL1853296T3 (pl) | 2012-12-31 |
| DK1853296T5 (da) | 2013-03-18 |
| WO2006072639A1 (fr) | 2006-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2611187T3 (es) | Tratamiento para hipertensión pulmonar | |
| Silachev et al. | The mitochondrion as a key regulator of ischaemic tolerance and injury | |
| CN104619710B (zh) | 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯 | |
| JP2001513495A (ja) | 外科的処置を容易にする組成物、装置および方法 | |
| Cheng et al. | Anaesthesia for non-cardiac surgery in heart-transplanted patients | |
| WO2002053167A2 (es) | Combinacion farmaceutica para el tratamiento del dano tisular debido a falta de irrigacion sanguinea arterial | |
| EP0484340B1 (en) | Treatment to reduce edema for brain and musculature injuries | |
| ES2382911T3 (es) | Método de cardioprotección y neuroprotección mediante administración intravenosa de anestésicos volátiles halogenados | |
| ES2651492T3 (es) | Composición acuosa pulverizable que comprende trinitrato de glicerilo | |
| PT1853296E (pt) | Utilização de um undecapeptídeo cíclico para a preparação de um medicamento para administração em situações de miocardia isquêmica | |
| JP2002534379A (ja) | 新規なブレチリウム組成物およびキットならびに心血管症状の予防および治療におけるそれらの使用 | |
| TW201806590A (zh) | 用於治療缺血再灌注損傷之戊二酸酯化合物 | |
| US5631226A (en) | Treatment to reduce edema | |
| TW201035091A (en) | 1,4-benzothiazepine-1-oxide derivatives and pharmaceutical composition using same | |
| WO2007143897A1 (fr) | Composé présentant une propriété spéciale, composition comprenant le composé, et sa préparation et ses utilisations | |
| Fan et al. | Remote ischemic preconditioning improves post resuscitation cerebral function via overexpressing neuroglobin after cardiac arrest in rats | |
| JP2018537522A (ja) | 組合せ | |
| CN117257803B (zh) | 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用 | |
| WO2016086327A1 (es) | Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, n-acetilcisteína, y deferoxamina; método de administración y uso en prevenir daño por reperfusión; y kit | |
| AU2013237021A1 (en) | Compounds for the treatment of ischemia-reperfusion- related diseases | |
| CN106421746A (zh) | [Pyr1]‑Apelin‑13 作为长效酰胺类局麻药中毒所致心脏停搏的抢救药物的应用 | |
| WO2001097831A1 (fr) | Agents therapeutiques et prophylactiques destines a l'insuffisance cardiaque | |
| JP2000026295A (ja) | 虚血再潅流損傷の治療薬ならび不整脈および心筋梗塞による心不全を含む細胞機能障害の治療薬 | |
| ES2235829T3 (es) | Utilizacion de moxonidina para el tratamiento post-infarto de corazon. | |
| SU1762932A1 (ru) | Способ профилактики острой сердечной недостаточности при операци х с искусственным кровообращением |